{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:44Z","timestamp":1792088204964,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.clinthera.2006.05.006","type":"journal-article","created":{"date-parts":[[2006,7,25]],"date-time":"2006-07-25T07:57:04Z","timestamp":1153814224000},"page":"652-665","source":"Crossref","is-referenced-by-count":66,"title":["Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus"],"prefix":"10.1016","volume":"28","author":[{"given":"Jason L.","family":"Iltz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danial E.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Setter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Keith Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.05.006_bib1","series-title":"National Diabetes Fact Sheet General Information and National Estimates on Diabetes in the United States, 2005","author":"Centers for Disease Control and Prevention","year":"2005"},{"key":"10.1016\/j.clinthera.2006.05.006_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/diacare.26.3.917","article-title":"Economic costs of diabetes in the U.S. in 2002","volume":"26","author":"Hogan","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.05.006_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jama.291.3.335","article-title":"Poor control of risk factors for vascu lar disease among adults with previously diagnosed diabetes","volume":"29","author":"Saydah","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.05.006_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.regpep.2004.07.014","article-title":"Glucagon-like peptide l and its derivatives in the treatment of diabetes","volume":"128","author":"Nauck","year":"2005","journal-title":"Regul Pept"},{"key":"10.1016\/j.clinthera.2006.05.006_bib5","first-page":"14","article-title":"Exenatide: Improves glycemic control in patients with type 2 diabetes mellitus","volume":"3","author":"Baker","year":"2005","journal-title":"Adv Pharm"},{"key":"10.1016\/j.clinthera.2006.05.006_bib6","first-page":"401","article-title":"Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes","volume":"4","author":"Neilson","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2006.05.006_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-0115(96)00135-8","article-title":"Bioactive peptides from lizard venoms","volume":"61","author":"Raufman","year":"1996","journal-title":"Regal Pept"},{"key":"10.1016\/j.clinthera.2006.05.006_bib8","doi-asserted-by":"crossref","first-page":"19650","DOI":"10.1016\/S0021-9258(19)36565-2","article-title":"Exendin-4 is a high potency agonist and truncated exendin-(9\u201339)-amide and antagonist at the glucagon-like peptide 1-(7\u201336)-amide receptor of insulin-secreting beta-cells","volume":"268","author":"Goke","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2006.05.006_bib9","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/nm1003-1228a","article-title":"Diabetes treatments get sweet help from nature","volume":"9","author":"Habeck","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2006.05.006_bib10","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2165\/00003495-200565120-00008","article-title":"Exenatide","volume":"65","author":"Keating","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2006.05.006_bib11","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","article-title":"Enhancing incretin action for the treatment of type 2 diabetes","volume":"26","author":"Drucker","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.05.006_bib12","series-title":"Exenatide injection","year":"2005"},{"key":"10.1016\/j.clinthera.2006.05.006_bib13","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2337\/diabetes.53.9.2397","article-title":"Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucosedependent insulin secretion and counterregulation during hypoglycemia","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2006.05.006_bib14","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.87.3.1282","article-title":"The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes","volume":"87","author":"Egan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.05.006_bib15","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exenatide) significantly reduces post-prandial and fasting plasma glucose in subjects with type 2 diabetes","volume":"88","author":"Kolterman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.05.006_bib16","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1210\/jc.2005-1093","article-title":"Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes","volume":"90","author":"Fehse","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.05.006_bib17","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/diacare.26.8.2370","article-title":"Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing mefformin and\/or sulfonylurea treatment in patients with type 2 diabetes","volume":"26","author":"Fineman","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.05.006_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide i n patients with type 2 diabetes mellitus","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am. J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2006.05.006_bib19","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1177\/0091270004274432","article-title":"Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects","volume":"45","author":"Blase","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.05.006_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nielson","year":"2004","journal-title":"Regal Pept"},{"key":"10.1016\/j.clinthera.2006.05.006_bib21","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/en.2004-1349","article-title":"Exenatide (exendin-4) improves insulin sensitivity and \u03b2-cell mass in insulin-resistant obese fa\/fa Zucker rats independent ofglycemia and bodyweight","volume":"146","author":"Gedulin","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2006.05.006_bib22","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1210\/en.141.6.1936","article-title":"Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats","volume":"141","author":"Szayna","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.clinthera.2006.05.006_bib23","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2006.05.006_bib24","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.05.006_bib25","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.05.006_bib26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2006.05.006_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clinthera.2005.02.008","article-title":"A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4)","volume":"27","author":"Calara","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2006.05.006_bib28","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1177\/0091270005278806","article-title":"Effect of exenatide on the steady-state pharmacokinetics of digoxin","volume":"45","author":"Kothare","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.05.006_bib29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1191\/0960327103ht402oa","article-title":"Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)","volume":"22","author":"Hiles","year":"2003","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.clinthera.2006.05.006_bib30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/dia.2005.7.467","article-title":"Exenatide improves glycemic control and reduces bodyweight in subjects with type 2 diabetes: A dose-ranging study","volume":"7","author":"Poon","year":"2005","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.clinthera.2006.05.006_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/dmrr.499","article-title":"Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes","volume":"20","author":"Fineman","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2006.05.006_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2006.05.006_bib33","unstructured":"Byetta\u00ae P&T QUIK\u00ae Reports. July 2005. Available at: http:\/\/www. thomsonhc.com. Accessed March 14, 2006."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T02:45:58Z","timestamp":1627613158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806001172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0149291806001172"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.05.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}